NYSE:RMD

ResMed Stock Forecast, Price & News

$269.73
+3.70 (+1.39 %)
(As of 07/29/2021 12:00 AM ET)
Add
Compare
Today's Range
$266.12
$269.98
50-Day Range
$202.14
$269.73
52-Week Range
$165.72
$269.98
Volume282,210 shs
Average Volume627,798 shs
Market Capitalization$39.25 billion
P/E Ratio86.18
Dividend Yield0.59%
Beta0.31
30 days | 90 days | 365 days | Advanced Chart
Receive RMD News and Ratings via Email

Sign-up to receive the latest news and ratings for ResMed and its competitors with MarketBeat's FREE daily newsletter.


ResMed logo

About ResMed

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links


MarketRank

Overall MarketRank

1.76 out of 5 stars

Medical Sector

596th out of 2,214 stocks

Surgical & Medical Instruments Industry

58th out of 185 stocks

Analyst Opinion: 2.1Community Rank: 2.7Dividend Strength: 1.7Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











ResMed (NYSE:RMD) Frequently Asked Questions

Is ResMed a buy right now?

14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ResMed in the last year. There are currently 2 sell ratings, 6 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ResMed stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RMD, but not buy additional shares or sell existing shares.
View analyst ratings for ResMed
or view top-rated stocks.

What stocks does MarketBeat like better than ResMed?

Wall Street analysts have given ResMed a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ResMed wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is ResMed's next earnings date?

ResMed is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for ResMed
.

How can I listen to ResMed's earnings call?

ResMed will be holding an earnings conference call on Thursday, August 5th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 201-612-7415 with passcode "13721425".

How were ResMed's earnings last quarter?

ResMed Inc. (NYSE:RMD) posted its quarterly earnings data on Thursday, April, 29th. The medical equipment provider reported $1.30 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $1.22 by $0.08. The medical equipment provider had revenue of $768.77 million for the quarter, compared to analysts' expectations of $784.47 million. ResMed had a net margin of 14.79% and a trailing twelve-month return on equity of 28.85%.
View ResMed's earnings history
.

How has ResMed's stock been impacted by Coronavirus?

ResMed's stock was trading at $153.61 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, RMD shares have increased by 75.6% and is now trading at $269.73.
View which stocks have been most impacted by COVID-19
.

How often does ResMed pay dividends? What is the dividend yield for ResMed?

ResMed announced a quarterly dividend on Thursday, April 29th. Shareholders of record on Thursday, May 13th will be paid a dividend of $0.39 per share on Thursday, June 17th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.58%. The ex-dividend date is Wednesday, May 12th.
View ResMed's dividend history
.

Is ResMed a good dividend stock?

ResMed pays an annual dividend of $1.56 per share and currently has a dividend yield of 0.59%. ResMed does not yet have a strong track record of dividend growth. The dividend payout ratio of ResMed is 32.77%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, ResMed will have a dividend payout ratio of 27.91% next year. This indicates that ResMed will be able to sustain or increase its dividend.
View ResMed's dividend history.

What price target have analysts set for RMD?

14 Wall Street analysts have issued twelve-month target prices for ResMed's stock. Their forecasts range from $210.00 to $270.00. On average, they anticipate ResMed's share price to reach $241.50 in the next twelve months. This suggests that the stock has a possible downside of 10.5%.
View analysts' price targets for ResMed
or view top-rated stocks among Wall Street analysts.

Who are ResMed's key executives?

ResMed's management team includes the following people:
  • Dr. Peter C. Farrell A.M., B.E., Ph.D., BE (Hons), ScD, AM, Founder & Non-Exec. Chairman (Age 79, Pay $431.8k)
  • Mr. Michael J. Farrell BE, SM, MBA, CEO & Director (Age 49, Pay $2.73M)
  • Mr. Robert A. Douglas, Pres & COO (Age 61, Pay $1.99M)
  • Mr. Brett A. Sandercock, Chief Financial Officer (Age 54, Pay $907.65k)
  • Dr. James R. Hollingshead Ph.D., Pres of Sleep & Respiratory Care Bus. (Age 58, Pay $1.27M)
  • Mr. Rajwant Singh Sodhi, Pres of Software as a Service Bus. (SaaS) (Age 48, Pay $1.04M)
  • Mr. Kaushik Ghoshal, Chief Technology Officer
  • Mr. David B. Pendarvis, Chief Admin. Officer, Global Gen. Counsel & Corp. Sec. (Age 62) (LinkedIn Profile)
  • Ms. Constance C. Bienfait, Director of Investor Relations
  • Ms. Amy Wakeham, VP of Investor Relations & Corp. Communications

What is Mick Farrell's approval rating as ResMed's CEO?

284 employees have rated ResMed CEO Mick Farrell on Glassdoor.com. Mick Farrell has an approval rating of 92% among ResMed's employees. This puts Mick Farrell in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of ResMed's key competitors?

What other stocks do shareholders of ResMed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ResMed investors own include NVIDIA (NVDA), The Walt Disney (DIS), Intel (INTC), AbbVie (ABBV), Netflix (NFLX), Adobe (ADBE), Visa (V), Alibaba Group (BABA), PayPal (PYPL) and QUALCOMM (QCOM).

What is ResMed's stock symbol?

ResMed trades on the New York Stock Exchange (NYSE) under the ticker symbol "RMD."

Who are ResMed's major shareholders?

ResMed's stock is owned by a number of retail and institutional investors. Top institutional investors include Welch & Forbes LLC (0.21%), Tandem Investment Advisors Inc. (0.07%), State of Alaska Department of Revenue (0.04%), LaFleur & Godfrey LLC (0.02%), Oregon Public Employees Retirement Fund (0.02%) and Eukles Asset Management (0.01%). Company insiders that own ResMed stock include Brett Sandercock, Dave Michaud, David Pendarvis, James Hollingshead, Justin Leong, Michael J Farrell, Rajwant Sodhi, Richard Mchale, Robert Andrew Douglas and Ronald R Taylor.
View institutional ownership trends for ResMed
.

Which institutional investors are selling ResMed stock?

RMD stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, Oregon Public Employees Retirement Fund, Harel Insurance Investments & Financial Services Ltd., Marshall Financial Group LLC, and Aptus Capital Advisors LLC. Company insiders that have sold ResMed company stock in the last year include Brett Sandercock, Dave Michaud, David Pendarvis, James Hollingshead, Justin Leong, Rajwant Sodhi, Robert Andrew Douglas, and Ronald R Taylor.
View insider buying and selling activity for ResMed
or view top insider-selling stocks.

Which institutional investors are buying ResMed stock?

RMD stock was bought by a variety of institutional investors in the last quarter, including Tandem Investment Advisors Inc., IFM Investors Pty Ltd, ST Germain D J Co. Inc., Brookstone Capital Management, LaFleur & Godfrey LLC, Eukles Asset Management, Welch & Forbes LLC, and Gofen & Glossberg LLC IL.
View insider buying and selling activity for ResMed
or or view top insider-buying stocks.

How do I buy shares of ResMed?

Shares of RMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ResMed's stock price today?

One share of RMD stock can currently be purchased for approximately $269.73.

How much money does ResMed make?

ResMed has a market capitalization of $39.25 billion and generates $2.96 billion in revenue each year. The medical equipment provider earns $621.67 million in net income (profit) each year or $4.76 on an earnings per share basis.

How many employees does ResMed have?

ResMed employs 7,770 workers across the globe.

When was ResMed founded?

ResMed was founded in 1989.

What is ResMed's official website?

The official website for ResMed is www.resmed.com.

Where are ResMed's headquarters?

ResMed is headquartered at 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA, 92123.

How can I contact ResMed?

ResMed's mailing address is 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA, 92123. The medical equipment provider can be reached via phone at 858-836-5000 or via email at [email protected]


This page was last updated on 7/30/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.